Exelixis (EXEL) to Release Earnings on Monday

Exelixis (NASDAQ:EXEL - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Monday, July 28th. Analysts expect Exelixis to post earnings of $0.63 per share and revenue of $574.36 million for the quarter.

Exelixis Trading Down 0.5%

Shares of Exelixis stock traded down $0.21 on Monday, hitting $44.26. 1,796,448 shares of the company traded hands, compared to its average volume of 2,535,035. The firm's 50-day simple moving average is $43.17 and its 200 day simple moving average is $38.47. The company has a market cap of $12.07 billion, a P/E ratio of 20.59, a P/E/G ratio of 0.89 and a beta of 0.28. Exelixis has a 12-month low of $22.20 and a 12-month high of $49.62.

Analysts Set New Price Targets

Several research firms recently commented on EXEL. Guggenheim set a $45.00 price objective on shares of Exelixis and gave the stock a "buy" rating in a research note on Thursday, May 15th. Wall Street Zen cut shares of Exelixis from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 15th. Citigroup increased their price objective on shares of Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Royal Bank Of Canada restated a "sector perform" rating and set a $50.00 target price (up previously from $45.00) on shares of Exelixis in a research report on Tuesday, July 8th. Finally, Jefferies Financial Group set a $50.00 price objective on shares of Exelixis and gave the company a "buy" rating in a research report on Tuesday, June 24th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Exelixis currently has an average rating of "Moderate Buy" and a consensus price target of $45.28.

Insider Buying and Selling at Exelixis

In other news, EVP Patrick J. Haley sold 34,387 shares of Exelixis stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $44.06, for a total value of $1,515,091.22. Following the transaction, the executive vice president directly owned 412,072 shares of the company's stock, valued at $18,155,892.32. The trade was a 7.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO Amy C. Peterson sold 72,776 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the completion of the transaction, the chief marketing officer directly owned 465,393 shares in the company, valued at $21,161,419.71. This represents a 13.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 458,113 shares of company stock worth $21,024,817. 2.85% of the stock is owned by insiders.

Institutional Investors Weigh In On Exelixis

Institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its holdings in shares of Exelixis by 4.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company's stock valued at $54,153,000 after purchasing an additional 68,133 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company's stock valued at $1,592,000 after purchasing an additional 19,407 shares during the last quarter. Focus Partners Wealth boosted its holdings in shares of Exelixis by 83.4% in the 1st quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company's stock valued at $1,420,000 after purchasing an additional 17,483 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Exelixis by 134.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company's stock valued at $61,000 after purchasing an additional 944 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.